Research progress on non-injection administration systems of paclitaxel
10.7501/j.issn.0253-2670.2019.17.005
- Author:
Xiu-Mei ZHANG
1
Author Information
1. School of Pharmaceutical Science and Technology, Tianjin University
- Publication Type:Journal Article
- Keywords:
Bioavailability;
Implantable delivery system;
Intranasal administration system;
Non-parenteral administration;
Oral administration system;
Paclitaxel;
Transdermal delivery system;
Vaginal administration systems
- From:
Chinese Traditional and Herbal Drugs
2019;50(17):4020-4030
- CountryChina
- Language:Chinese
-
Abstract:
Paclitaxel (PTX) is a complex secondary metabolite isolated from Taxus brevifolia, which widely used as chemotherapentic agent with a broad spectrum of actinity against cancer in the world. Its water solubility was poor and oral bioavailability was low. Cremophor-EL was used in traditional PTX injections to improve the solubility of PTX, and resulted in several adverse side effects such as severe hypersensitivity. Pre-desensitization treatment was needed before clinical use. Recently, a variety of non-injection drug delivery systems (DDS) of PTX have been developed. In this paper, the research progress of non-parenteral PTX was reviewed, including oral administration systems, vaginal administration systems, transdermal DDS, implantable DDS, transdermal DDS, intranasal administration and inhalation DDS, so as to provide references for future study and clinical applications.
